Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Gastroenterology

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2007.12.012PMID 18325386PMCID PMC2276587
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

  2008cited by this paper
• Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents

  2007cited by this paper
• Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis

  2007cited by this paper
• Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression.

  2007cited by this paper
• A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

  2007cited by this paper
• Coronary heart disease outcomes in patients receiving antidiabetic agents

  2007cited by this paper
• Safety issues and prospects for future generations of PPAR modulators.

  2007cited by this paper
• A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis.

  2007cited by this paper
• Placebo Response in Two Long-Term Randomized Psoriasis Studies that were Negative for Rosiglitazone

  2007cited by this paper
• Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

  2007cited by this paper
• A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

  2007cited by this paper
• Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

  2007cited by this paper
• Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease.

  2006cited by this paper
• PPARgamma as a new therapeutic target in inflammatory bowel diseases.

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• PPARγ as a new therapeutic target in inflammatory bowel diseases

  2006cited by this paper
• A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ

  2005cited by this paper
• Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis?

  2005cited by this paper
• Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease

  2005cited by this paper
• Mantel–Haenszel Methods

  2005cited by this paper
• Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease

  2005cited by this paper
• Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

  2005cited by this paper
• Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ

  2005cited by this paper
• A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.

  2004cited by this paper
• Role of PPARgamma in macrophage biology and atherosclerosis.

  2004cited by this paper
• Role of PPARγ in macrophage biology and atherosclerosis

  2004cited by this paper
• Inflammatory bowel disease and the risk of fracture.

  2003cited by this paper
• An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis

  2001cited by this paper
• An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• The risk of colorectal cancer in ulcerative colitis: a meta-analysis

  2001cited by this paper
• Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

  2000cited by this paper
• Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease.

  1999cited by this paper
• A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.

  1999influential reference
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997influential reference
• Quantification of the placebo response in ulcerative colitis.

  1997influential reference
• The nuclear receptor superfamily: the second decade.

  1995cited by this paper
• The impact of confounder selection criteria on effect estimation.

  1989cited by this paper
• 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

  1987cited by this paper
• 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada

  1987cited by this paper
• Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

  1987cited by this paper
• Clinical Trials: Design, Conduct, and Analysis

  1986cited by this paper

• PPAR-γ Activation Alleviates Intestinal Dysfunction and Lactose Malabsorption in Experimental Food Allergy Rats.

  2026cites this paper
• The importance of mitochondria and mitochondrial calcium signaling in health and disease: an updated outlook on inflammation.

  2026cites this paper
• Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review.

  2026cites this paper
• Molecular Docking, Dynamics, and Preclinical Studies Reveal Morin Hydrate as a Potent PPARγ and Nrf2 Agonist That Mitigates Colon Inflammation

  2025cites this paper
• Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies.

  2025cites this paper
• Potentials of peroxisome proliferator-activated receptor (PPAR) α, β/δ, and γ: An in-depth and comprehensive review of their molecular mechanisms, cellular Signalling, immune responses and therapeutic implications in multiple diseases.

  2025cites this paper
• CRIF1 gene therapy ameliorates inflammatory bowel disease by suppressing TH17 cells and fibrosis through mitochondrial function regulation

  2025cites this paper
• A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

  2025cites this paper
• Activation of PPARγ regulates M1/M2 macrophage polarization and attenuates dextran sulfate sodium salt‐induced inflammatory bowel disease via the STAT‐1/STAT‐6 pathway

  2024cites this paper
• The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases

  2024cites this paper
• The landscape of new therapeutic opportunities for IBD.

  2024cites this paper
• Gut-derived PPAR-γ signaling and risk of bacterial enteric infection: insight from thiazolidinedione users in a US population-based study

  2024cites this paper
• Drugs and Their Mode of Action: A Review on Sulfur-Containing Heterocyclic Compounds

  2024cites this paper
• Type 2 diabetes and inflammatory bowel disease: a bidirectional two-sample Mendelian randomization study

  2024cites this paper
• Association of Antidiabetic Drug Target Genes with Inflammatory Bowel Disease: A Mendelian Randomization Study

  2024cites this paper
• Mitochondrial function and gastrointestinal diseases

  2024cites this paper
• Bifidobacterium bifidum strain BB1 inhibits TNF-α-induced increase in intestinal epithelial tight junction permeability via TLR-2/TLR-6 receptor complex-dependent stimulation of PPAR-γ and suppression of NF-kB p65.

  2024cites this paper
• Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study.

  2024cites this paper
• AMPK activation alleviated dextran sulfate sodium‐induced colitis by inhibiting ferroptosis

  2023cites this paper
• Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease

  2023cites this paper
• Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma

  2023cites this paper
• M2a macrophages facilitate resolution of chemically-induced colitis in TLR4-SNP mice

  2023cites this paper
• Theabrownins prevents DSS-induced colitis via modulating PPAR-γ and NF-κB signaling pathways in mice

  2023cites this paper
• Impact of Obesity on the Course of Management of Inflammatory Bowel Disease—A Review

  2022cites this paper
• Peroxisome proliferator-activated receptor-γ as the gatekeeper of tight junction in Clostridioides difficile infection

  2022cites this paper
• Ghrelin Alleviates Experimental Ulcerative Colitis in Old Mice and Modulates Colonocyte Metabolism via PPARγ Pathway

  2022cites this paper
• Pioglitazone Attenuates the Effects of Peripheral Inflammation in a Human In Vitro Blood–Brain Barrier Model

  2022cites this paper
• Gut Microbiota: The Potential Key Target of TCM’s Therapeutic Effect of Treating Different Diseases Using the Same Method—UC and T2DM as Examples

  2022cites this paper
• Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: Results from a systematic review of induction studies.

  2022cites this paper
• Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

  2021cites this paper
• AI-guided use of balanced PPARα/g dual agonist finetunes

  2021cites this paper
• Chinese Herbs and Repurposing Old Drugs as Therapeutic Agents in the Regulation of Oxidative Stress and Inflammation in Pulmonary Diseases

  2021cites this paper
• Potential therapeutic uses of rexinoids.

  2021cites this paper
• Colonic Medium-Chain Fatty Acids Act as a Source of Energy and for Colon Maintenance but Are Not Utilized to Acylate Ghrelin

  2021cites this paper
• Estrogen-related receptor alpha (ERRα) is a key regulator of intestinal homeostasis and protects against colitis

  2021cites this paper
• Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease

  2021cites this paper
• 5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium

  2021cites this paper
• Intestinal Microbial Metabolites in Ankylosing Spondylitis

  2021cites this paper
• Regulation of the germinal center response by nuclear receptors and implications for autoimmune diseases

  2020cites this paper
• Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation

  2020cites this paper
• Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine

  2020cites this paper
• Pioglitazone-Mediated Attenuation of Experimental Colitis Relies on Cleaving of Annexin A1 Released by Macrophages

  2020cites this paper
• MicroRNA-511-3p mediated modulation of the peroxisome proliferator-activated receptor gamma (PPARγ) controls LPS-induced inflammatory responses in human monocyte derived DCs

  2020cites this paper
• PPARs and Microbiota in Skeletal Muscle Health and Wasting

  2020cites this paper
• Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity

  2020cites this paper
• Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm

  2020cites this paper
• Ulcerative colitis is characterized by amplified acute inflammation with delayed resolution

  2019cites this paper
• The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis.

  2019cites this paper
• Network pharmacology-based identification of the protective mechanisms of taraxasterol in experimental colitis.

  2019cites this paper
• Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.

  2019cites this paper
• The Role of Adipose Tissue in the Pathogenesis and Therapeutic Outcomes of Inflammatory Bowel Disease

  2019cites this paper
• Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

  2019cites this paper
• Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD

  2019cites this paper
• Endothelial PPARγ Is Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK

  2019cites this paper
• Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease

  2019cites this paper
• Plant Science Today

  2019cites this paper
• Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis

  2018cites this paper
• Linoorbitides and enterolactone mitigate inflammation‐induced oxidative stress and loss of intestinal epithelial barrier integrity

  2018cites this paper
• Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

  2018cites this paper
• Impact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and Inflammation

  2018cites this paper
• Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5)

  2018cites this paper
• Interaction between smoking and ATG 16 L 1 T 300 A triggers Paneth cell defects in Crohn ’ s disease

  2018influential citation
• The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development

  2018cites this paper
• Bergenin, Acting as an Agonist of PPARγ, Ameliorates Experimental Colitis in Mice through Improving Expression of SIRT1, and Therefore Inhibiting NF-κB-Mediated Macrophage Activation

  2018cites this paper
• Review article: novel oral‐targeted therapies in inflammatory bowel disease

  2018cites this paper
• Enteric Microbiota–Gut–Brain Axis from the Perspective of Nuclear Receptors

  2018cites this paper
• Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine

  2018cites this paper
• A Novel Topical PPARγ Agonist Induces PPARγ Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models.

  2018cites this paper
• PPARγ et homéostasie intestinale

  2018cites this paper
• Interaction between smoking and ATG16L1T300A triggers Paneth cell defects in Crohn’s disease

  2018cites this paper
• The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis

  2017cites this paper
• Tricellular junction regulation, signaling and scaffolding

  2017cites this paper
• Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations

  2017cites this paper
• Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers

  2017cites this paper
• Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set

  2017cites this paper
• PPARγ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium

  2017cites this paper
• Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

  2017cites this paper
• A Systems Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Xipayi KuiJie’an enema for Treatment of Ulcerative colitis

  2017cites this paper
• Metabolic Regulation of T Cell Immunity.

  2017cites this paper
• Siegesbeckia pubescens ameliorates experimentalulcerative colitis in rats by modulating PPARγ

  2016cites this paper
• Synthetic optimization of rosiglitazone and related intermediates for industrial purposes

  2016cites this paper
• Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction

  2016cites this paper
• Targeting STAT1 in Both Cancer and Insulin Resistance Diseases.

  2016cites this paper
• Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.

  2016cites this paper
• Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

  2016cites this paper
• Modulation of inflammation and immunity by dietary conjugated linoleic acid.

  2016cites this paper
• Anti-inflammatory effects of docosahexaenoic acid: Implications for its cancer chemopreventive potential.

  2016cites this paper
• Docosahexaenoic acid inhibits Helicobacter pylori-induced STAT3 phosphorylation through activation of PPARγ.

  2016cites this paper
• Primary cicatricial alopecia and inflammatory bowel disease – is there a link?

  2016cites this paper
• Do anti‐hypertensive renin‐angiotensin system inhibitors contribute to the development of classical Kaposi sarcoma?

  2016cites this paper
• Adipokines and the role of visceral adipose tissue in inflammatory bowel disease

  2016cites this paper
• New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract.

  2015cites this paper
• 5-Aminosalicylic acid, a specific drug for ulcerative colitis

  2015cites this paper
• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  2015cites this paper
• Modulation of peroxisome proliferator-activated receptor gamma (PPAR γ) by conjugated fatty acid in obesity and inflammatory bowel disease.

  2015cites this paper
• Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

  2015cites this paper
• Transdisciplinary Strategies for the Characterization of Mucosal Immune Responses to Enteric Pathogens

  2015cites this paper
• Mapping the effects of drugs on the immune system

  2015cites this paper
• Effects of Resistant Starch and Arabinoxylan on Parameters Related to Large Intestinal and Metabolic Health in Pigs Fed Fat-Rich Diets.

  2015cites this paper
• Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.

  2015cites this paper